Amprion’s mission: To revolutionize brain disease diagnosis. Through molecular testing, we aim to accelerate precision medicine for neurodegenerative disorders.
As a pioneer in Prion Detection Science®, we believe precision medicine is the new frontier. We strive to positively impact brain disease diagnosis and treatment as the world population ages rapidly. See our evolving scientific journey below.
Neuroscientist Claudio Soto teams up with molecular pathologist Dr. Russ Lebovitz to work on detecting prions, aka misfolded proteins, relating to Creutzfeldt-Jakob Disease (CJD).
As mad cow disease dissipates, the team pivots, asking: Is there a parallel between misfolded proteins in mad cow disease and human brain disorders?
Dr. Soto proves there is a similarity and develops an assay to detect misfolded Abeta, a biomarker found in most Alzheimer’s patients.
The team expands research to detect other misfolded proteins, including Synuclein and Tau.
Revolutionize molecular testing to help doctors diagnose brain diseases accurately.
Amprion expands its lab, conducting further scientific research using its proprietary Prion Detection Science®.
The company establishes a state-of-the-art clinical lab run by dedicated scientists and experts, not to mention tireless bots when humans are off the clock.
The US FDA awards Amprion Breakthrough Device Designation for detecting misfolded Synuclein, a key brain disease biomarker.
Dr. Soto published a research article in Nature.
Team Amprion, standing 6-feet apart, worked through Covid and reached a significant milestone. We achieved CLIA approval for our clinical lab.
Our first biomarker test helps doctors diagnose Parkinson’s, and Lewy Body Dementia by detecting misfolded Synuclein in CSF. This test is developed and validated by a licensed physician pathologist in our CAP-accredited clinical laboratory.
A pioneer in the science of detecting mis-folded proteins, Amprion advances the diagnosis of brain disorders. Our SYNTap™️ Biomarker Test aids physicians in diagnosing Parkinson’s, Lewy Body Dementia, and Alzheimer’s with Lewy Body variant. We plan to launch more biomarker tests in the future.